The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

DLA Piper LLP (US)

Larry Nishnick

Tel:
Work 1 858 677 1414
Email:
DLA Piper LLP (US)

Work Department

Emerging Companies

Position

Partner

Career

 

 

Larry Nishnick advises both private emerging growth companies and established, public company clients throughout a broad range of industries, including technology, software, life sciences and healthcare, sports, media, entertainment, consumer products and retail, consumer finance, cleantech and the internet of things. Larry also advises private equity, venture capitalists and angel investors in connection with their investments.

 

Larry advises clients from the initial formation and early-stage fundraisings through later-stage venture capital and private equity financings to IPOs and follow-on offerings, PIPEs and debt financings. Larry has extensive experience in mergers and acquisitions, joint ventures, partnerships, collaborations and other strategic transactions. Larry's practice also includes SEC disclosure and reporting requirements, including 1933 Act and 1934 Act disclosure and the reporting requirements of NYSE, NASDAQ and AMEX.

 

Education

JD, University of San Diego School of Law; BA, Washington & Jefferson College


United States: Industry focus

Healthcare: life sciences

Within: Next generation lawyers

Larry Nishnick - DLA Piper LLP (US)

Within: Healthcare: life sciences

DLA Piper LLP (US)’s ‘excellent, responsive and knowledgeable’ department has considerable experience assisting high-profile clients with regulatory, transactional and IP matters, as well as complex global disputes. San Diego-based co-head Lisa Haile and New York-based Stuart Pollack have been leading advice to SteadyMed on various patent invalidation claims brought against United Therapeutics before the Patent Trial and Appeal Board (PTAB). Co-head Richard Mulloy and Drew Wintringham, who are in San Diego and New York, respectively, have been representing Covidien in patent litigation brought against Ethicon arising from the release of Ethicon’s Enseal X1 medical device. The team also acted for Sanpower Group on its $820m acquisition of Dendreon Pharmaceuticals. Also led by product liability expert Matthew Holian in Boston, the team includes George Karavetsos in Miami, Loren Brown in New York, Raymond Williams in Philadelphia, Larry Nishnick in San Diego and Aaron Fountain, who splits his time between Austin and Houston.

[back to top]


Back to index

Legal Developments by:
DLA Piper LLP (US)

  • Sentencing guidelines for corporate manslaughter

    In February 2010 the Sentencing Guidelines Council (the SGC) issued definitive guidelines to courts on imposing appropriate sentences for corporate manslaughter and health and safety offences causing death. The SGC states that fines imposed on companies found guilty of corporate manslaughter should not fall below £500,000, while fines in respect of health and safety offences that are a significant cause of death should be at least £100,000. Crucially, the SGC declined to provide for a fixed link between the imposed fine and the turnover or profitability of the offending company.

    - DLA Piper UK LLP

Legal Developments worldwide

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to